Advertisement

Prescription Drugs Used in Insomnia

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Sleep Medicine Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • van Straten A.
        • van der Zweerde T.
        • Kleiboer A.
        • et al.
        Cognitive and behavioral therapies in the treatment of insomnia: a meta-analysis.
        Sleep Med Rev. 2018; 38: 3-16
        • Sateia M.J.
        • Buysse D.J.
        • Krystal A.D.
        • et al.
        Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: an American Academy of Sleep Medicine clinical practice guideline.
        J Clin Sleep Med. 2017; 13: 307-349
        • Riemann D.
        • Baglioni C.
        • Bassetti C.
        • et al.
        European guideline for the diagnosis and treatment of insomnia.
        J Sleep Res. 2017; 26: 675-700
        • Morin C.M.
        • Vallieres A.
        • Guay B.
        • et al.
        Cognitive behavioral therapy, singly and combined with medi- cation, for persistent insomnia: a randomized controlled trial.
        JAMA. 2009; 301: 2005-2015
        • Zavesicka L.
        • Brunovsky M.
        • Matousek M.
        • et al.
        Discon tinuation of hypnotics during cognitive behavioural therapy for insomnia.
        BMC Psychiatry. 2008; 8: 80
        • Winkler A.
        • Rief W.
        Effect of placebo conditions on polysomnographic parameters in primary insomnia: a meta-analysis.
        Sleep. 2015; 38: 925-931
        • Yeung V.
        • Sharpe L.
        • Glozier N.
        • et al.
        A systematic re- view and meta-analysis of placebo versus no treat- ment for insomnia symptoms.
        Sleep Med Rev. 2018; 38: 17-27
        • Krystal A.D.
        A compendium of placebo-controlled tri als of the risks/benefits of pharmacological treat ments for insomnia: the empirical basis for U.S. clinical practice.
        Sleep Med Rev. 2009; 13: 265-274
        • Minkel J.
        • Krystal A.D.
        Optimizing the pharmacologic treatment of insomnia: current status and future ho- rizons.
        Sleep Med Clin. 2013; 8: 333-350
        • Wafford K.A.
        • Ebert B.
        Emerging anti-insomnia drugs: tackling sleeplessness and the quality of wake time.
        Nat Rev Drug Discov. 2008; 7: 530-540
        • Lu J.
        • Greco M.A.
        Sleep circuitry and the hypnotic mechanism of GABAA drugs.
        J Clin Sleep Med. 2006; 2: S19-S26
        • Saper C.B.
        • Scammell T.E.
        • Lu J.
        Hypothalamic regula tion of sleep and circadian rhythms.
        Nature. 2005; 437: 1257-1263
        • Mendelson W.
        • Laposky A.
        Effects of triazolam micro injections into the peri-fornicular region on sleep in rats.
        Sleep Hypnosis. 2003; 5: 154-162
        • Nestler E.J.
        • Hyman S.
        • Holtzmann D.M.
        • et al.
        Molecu- lar neuropharmacology: a foundation for clinical neuroscience.
        3rd edition. McGraw-Hill Medical, New York2015
        • Rudolph U.
        • Crestani F.
        • Benke D.
        • et al.
        Benzodiaze pine actions mediated by specific gamma- aminobutyric acid(A) receptor subtypes.
        Nature. 1999; 401: 796-800
        • Glass J.R.
        • Sproule B.A.
        • Herrmann N.
        • et al.
        Effects of 2-week treatment with temazepam and diphenhy- dramine in elderly insomniacs: a randomized, placebo-controlled trial.
        J Clin Psychopharmacol. 2008; 28: 182-188
        • Wu R.
        • Bao J.
        • Zhang C.
        • et al.
        Comparison of sleep condition and sleep-related psychological activity after cognitive-behavior and pharmacological ther- apy for chronic insomnia.
        Psychother Psychosom. 2006; 75: 220-228
        • Roehrs T.
        • Bonahoom A.
        • Pedrosi B.
        • et al.
        Treatment regimen and hypnotic self-administration.
        Psycho Pharmacol (Berl). 2001; 155: 11-17
        • Oswald I.
        • French C.
        • Adam K.
        • et al.
        Benzodiazepine hypnotics remain effective for 24 weeks.
        Br Med J (Clin Res Ed). 1982; 284: 860-863
        • Janhsen K.
        • Roser P.
        • Hoffmann K.
        The problems of long-term treatment with benzodiazepines and related substances.
        Dtsch Arztebl Int. 2015; 112: 1-7
        • Campanelli C.
        American Geriatrics Society updated beers criteria for potentially inappropriate medica- tion use in older adults: the American Geriatrics So- ciety 2012 beers criteria update expert panel.
        J Am Geriatr Soc. 2012; 60: 616-631
        • Luyster F.S.
        • Buysse D.J.
        • Strollo Jr., P.J.
        Comorbid insomnia and obstructive sleep apnea: challenges for clinical practice and research.
        J Clin Sleep Med. 2010; 6: 196-204
        • Roehrs T.
        • Roth T.
        Drug-related sleep stage changes: functional significance and clinical relevance.
        Sleep Med Clin. 2010; 5: 559-570
        • Bastien C.H.
        • LeBlanc M.
        • Carrier J.
        • et al.
        Sleep EEG power spectra, insomnia, and chronic use of benzo diazepines.
        Sleep. 2003; 26: 313-317
        • Borbely A.A.
        • Mattmann P.
        • Loepfe M.
        • et al.
        Effect of benzodiazepine hypnotics on all-night sleep EEG spectra.
        Hum Neurobiol. 1985; 4: 189-194
        • Kilduff T.
        • Mendelson W.B.
        Hypnotic medications: mechanisms of action and pharmacologic effects.
        in: Kryger M. Roth T. Principles and practice of sleep medicine. 6th edition. Elsevier, Philadelphia2017: 425-431
        • Mazza M.
        • Losurdo A.
        • Testani E.
        • et al.
        Polysomno graphy findings in a cohort of chronic insomnia pa tients with benzodiazepine abuse.
        J Clin Sleep Med. 2014; 10: 35-42
        • Royant-Parola S.
        • Brion A.
        • Poirot I.
        Prise en charge de l'insomnie: guide pratique.
        Elsevier Masson SAS, Issy-les-Moulineaux (France)2017
        • Stahl S.M.
        Stahl's essential psychopharmacology: neuroscientific basis and practical applications.
        Cambridge University Press, Cambridge (England)2013
        • Holm K.J.
        • Goa K.L.
        Zolpidem: an update of its phar macology, therapeutic efficacy and tolerability in the treatment of insomnia.
        Drugs. 2000; 59: 865-889
        • Wishart D.S.
        • Feunang Y.D.
        • Guo A.C.
        • et al.
        DrugBank 5.0: a major update to the DrugBank database for 2018.
        Nucleic Acids Res. 2018; 46: D1074-D1082
        • Drover D.R.
        Comparative pharmacokinetics and pharmacodynamics of short-acting hypnosedatives: zaleplon, zolpidem and zopiclone.
        Clin Pharmacokinet. 2004; 43: 227-238
        • Erman M.K.
        • Zammit G.
        • Rubens R.
        • et al.
        A polysomnographic placebo-controlled evaluation of the efficacy and safety of eszopiclone relative to placebo and zolpidem in the treatment of primary insomnia.
        J Clin Sleep Med. 2008; 4: 229-234
        • Walsh J.K.
        • Vogel G.W.
        • Scharf M.
        • et al.
        A five week, polysomnographic assessment of zaleplon 10 mg for the treatment of primary insomnia.
        Sleep Med. 2000; 1: 41-49
        • Gunja N.
        In the Zzz zone: the effects of Z-drugs on human performance and driving.
        J Med Toxicol. 2013; 9: 163-171
        • Becker P.M.
        • Somiah M.
        Non-benzodiazepine recep- tor agonists for insomnia.
        Sleep Med Clin. 2015; 10: 57-76
        • Krystal A.D.
        • Walsh J.K.
        • Laska E.
        • et al.
        Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia.
        Sleep. 2003; 26: 793-799
        • Wadworth A.N.
        • McTavish D.
        Zopiclone. A review of its pharmacological properties and therapeutic efficacy as an hypnotic.
        Drugs Aging. 1993; 3: 441-459
        • Toner L.C.
        • Tsambiras B.M.
        • Catalano G.
        • et al.
        Central nervous system side effects associated with zolpi- dem treatment.
        Clin Neuropharmacol. 2000; 23: 54-58
        • Chen Y.W.
        • Tseng P.T.
        • Wu C.K.
        • et al.
        Zaleplon-induced anemsic somnambulism with eating behaviors under once dose.
        Acta Neurol Taiwan. 2014; 23: 143-145
        • Treves N.
        • Perlman A.
        • Kolenberg Geron L.
        • et al.
        Z- drugs and risk for falls and fractures in older adults: a systematic review and meta-analysis.
        Age Ageing. 2018; 47: 201-208
        • Orriols L.
        • Philip P.
        • Moore N.
        • et al.
        Benzodiazepine- like hypnotics and the associated risk of road traffic accidents.
        Clin Pharmacol Ther. 2011; 89: 595-601
        • Chang C.M.
        • Wu E.C.
        • Chen C.Y.
        • et al.
        Psychotropic drugs and risk of motor vehicle accidents: a population-based case-control study.
        Br J Clin Pharmacol. 2013; 75: 1125-1133
        • Mahler S.V.
        • Moorman D.E.
        • Smith R.J.
        • et al.
        Motiva tional activation: a unifying hypothesis of orexin/hypocretin function.
        Nat Neurosci. 2014; 17: 1298-1303
        • Bonnavion P.
        • de Lecea L.
        Hypocretins in the control of sleep and wakefulness.
        Curr Neurol Neurosci Rep. 2010; 10: 174-179
        • Sakurai T.
        • Amemiya A.
        • Ishii M.
        • et al.
        Orexins and orexin receptors: a family of hypothalamic neuro- peptides and G protein-coupled receptors that regulate feeding behavior.
        Cell. 1998; 92: 573-585
        • de Lecea L.
        • Kilduff T.S.
        • Peyron C.
        • et al.
        The hypocre tins: hypothalamus-specific peptides with neuroex- citatory activity.
        Proc Natl Acad Sci U S A. 1998; 95: 322-327
        • Law V.
        • Knox C.
        • Djoumbou Y.
        • et al.
        DrugBank 4.0: shedding new light on drug metabolism.
        Nucleic Acids Res. 2014; 42: D1091-D1097
        • Herring W.J.
        • Connor K.M.
        • Ivgy-May N.
        • et al.
        Suvorex- ant in patients with insomnia: results from two 3-month randomized controlled clinical trials.
        Biol Psychiatry. 2016; 79: 136-148
        • Herring W.J.
        • Snyder E.
        • Budd K.
        • et al.
        Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexant.
        Neurology. 2012; 79: 2265-2274
        • Michelson D.
        • Snyder E.
        • Paradis E.
        • et al.
        Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discon tinuation: a phase 3 randomised, double-blind, pla- cebo-controlled trial.
        Lancet Neurol. 2014; 13: 461-471
        • Herring W.J.
        • Connor K.M.
        • Snyder E.
        • et al.
        Suvorex ant in patients with insomnia: pooled analyses of three-month data from phase-3 randomized controlled clinical trials.
        J Clin Sleep Med. 2016; 12: 1215-1225
        • Snyder E.
        • Ma J.
        • Svetnik V.
        • et al.
        Effects of suvorex- ant on sleep architecture and power spectral profile in patients with insomnia: analysis of pooled phase 3 data.
        Sleep Med. 2016; 19: 93-100
      1. Sun H, Palcza J, Card D, et al. Effects of suvorexant, an orexin receptor antagonist, on respiration during sleep in patients with obstructive sleep apnea. J Clin Sleep Med 2016;12(1):9–17.

        • Sun H.
        • Palcza J.
        • Rosenberg R.
        • et al.
        Effects of su- vorexant, an orexin receptor antagonist, on breath ing during sleep in patients with chronic obstructive pulmonary disease.
        Respir Med. 2015; 109: 416-426
        • Uemura N.
        • McCrea J.
        • Sun H.
        • et al.
        Effects of the orexin receptor antagonist suvorexant on respiration during sleep in healthy subjects.
        J Clin Pharmacol. 2015; 55: 1093-1100
        • Tabata H.
        • Kuriyama A.
        • Yamao F.
        • et al.
        Suvorexant- induced dream enactment behavior in Parkinson disease: a case report.
        J Clin Sleep Med. 2017; 13: 759-760
        • Petrous J.
        • Furmaga K.
        Adverse reaction with suvor- exant for insomnia: acute worsening of depression with emergence of suicidal thoughts.
        BMJ Case Rep. 2017;
        • Pevet P.
        Melatonin receptors as therapeutic targets in the suprachiasmatic nucleus.
        Expert Opin Ther Targets. 2016; 20: 1209-1218
        • Liu C.
        • Weaver D.R.
        • Jin X.
        • et al.
        Molecular dissection of two distinct actions of melatonin on the supra chiasmatic circadian clock.
        Neuron. 1997; 19: 91-102
        • Liu J.
        • Clough S.J.
        • Hutchinson A.J.
        • et al.
        MT1 and MT2 melatonin receptors: a therapeutic perspective.
        Annu Rev Pharmacol Toxicol. 2016; 56: 361-383
        • Pandi-Perumal S.R.
        • Trakht I.
        • Srinivasan V.
        • et al.
        Phys- iological effects of melatonin: role of melatonin re- ceptors and signal transduction pathways.
        Prog Neurobiol. 2008; 85: 335-353
        • Andersen L.P.
        • Werner M.U.
        • Rosenkilde M.M.
        • et al.
        Pharmacokinetics of oral and intravenous melatonin in healthy volunteers.
        BMC Pharmacol Toxicol. 2016; 17: 8
        • Harpsoe N.G.
        • Andersen L.P.
        • Gogenur I.
        • et al.
        Clinical pharmacokinetics of melatonin: a systematic review.
        Eur J Clin Pharmacol. 2015; 71: 901-909
        • Sateia M.J.
        • Kirby-Long P.
        • Taylor J.L.
        Efficacy and clin ical safety of ramelteon: an evidence-based review.
        Sleep Med Rev. 2008; 12: 319-322
        • Slawik H.
        • Stoffel M.
        • Riedl L.
        • et al.
        Prospective study on salivary evening melatonin and sleep before and after pinealectomy in humans.
        J Biol Rhythms. 2016; 31: 82-93
        • Auld F.
        • Maschauer E.L.
        • Morrison I.
        • et al.
        Evidence for the efficacy of melatonin in the treatment of primary adult sleep disorders.
        Sleep Med Rev. 2017; 34: 10-22
        • Ferracioli-Oda E.
        • Qawasmi A.
        • Bloch M.H.
        Meta-anal- ysis: melatonin for the treatment of primary sleep disorders.
        PLoS One. 2013; 8: e63773
        • Stone B.M.
        • Turner C.
        • Mills S.L.
        • et al.
        Hypnotic activity of melatonin.
        Sleep. 2000; 23: 663-669
        • Arbon E.L.
        • Knurowska M.
        • Dijk D.J.
        Randomised clin ical trial of the effects of prolonged-release melatonin, temazepam and Zolpidem on slow-wave activity during sleep in healthy people.
        J Psychopharmacol. 2015; 29: 764-776
        • Mayer G.
        • Wang-Weigand S.
        • Roth-Schechter B.
        • et al.
        Efficacy and safety of 6-month nightly ramelteon administration in adults with chronic primary insomnia.
        Sleep. 2009; 32: 351-360
        • Wade A.G.
        • Ford I.
        • Crawford G.
        • et al.
        Nightly treatment of primary insomnia with prolonged release mela- tonin for 6 months: a randomized placebo controlled trial on age and endogenous melatonin as predictors of efficacy and safety.
        BMC Med. 2010; 8: 51
        • Tordjman S.
        • Chokron S.
        • Delorme R.
        • et al.
        Melatonin: pharmacology, functions and therapeutic benefits.
        Curr Neuropharmacol. 2017; 15: 434-443
      2. (Available at) (Accessed January 22, 2018)
        • Krystal A.D.
        Antidepressant and antipsychotic drugs.
        Sleep Med Clin. 2010; 5: 571-589
        • DeMartinis N.A.
        • Winokur A.
        Effects of psychiatric medications on sleep and sleep disorders.
        CNS Neurol Disord Drug Targets. 2007; 6: 17-29
        • Buysse D.J.
        • Tyagi S.
        Clinical pharmacology of other drugs used as hypnotics.
        in: Kryger M. Roth T. Principles and practice of sleep medicine. 6th edition. Elsevier, Philadelphia2017: 432-445
        • Lankford A.
        • Rogowski R.
        • Essink B.
        • et al.
        Efficacy and safety of doxepin 6 mg in a four-week outpatient trial of elderly adults with chronic primary insomnia.
        Sleep Med. 2012; 13: 133-138
        • Scharf M.
        • Rogowski R.
        • Hull S.
        • et al.
        Efficacy and safety of doxepin 1 mg, 3 mg, and 6 mg in elderly patients with primary insomnia: a randomized, double-blind, placebo-controlled crossover study.
        J Clin Psychiatry. 2008; 69: 1557-1564
        • Krystal A.D.
        • Durrence H.H.
        • Scharf M.
        • et al.
        Efficacy and safety of doxepin 1 mg and 3 mg in a 12- week sleep laboratory and outpatient trial of elderly subjects with chronic primary insomnia.
        Sleep. 2010; 33: 1553-1561
        • Liu Y.
        • Xu X.
        • Dong M.
        • et al.
        Treatment of insomnia with tricyclic antidepressants: a meta-analysis of poly- somnographic randomized controlled trials.
        Sleep Med. 2017; 34: 126-133
        • Walsh J.K.
        • Erman M.
        • Erwin C.W.
        • et al.
        Subjective hypnotic efficacy of trazodone and zolpidem in DSMIII- R primary insomnia.
        Hum Psychopharmacol. 1998; 13: 191-198
        • Montgomery I.
        • Oswald I.
        • Morgan K.
        • et al.
        Trazodone enhances sleep in subjective quality but not in objective duration.
        Br J Clin Pharmacol. 1983; 16: 139-144
        • Roth A.J.
        • McCall W.V.
        • Liguori A.
        Cognitive, psycho- motor and polysomnographic effects of trazodone in primary insomniacs.
        J Sleep Res. 2011; 20: 552-558
        • Schmid D.A.
        • Wichniak A.
        • Uhr M.
        • et al.
        Changes of sleep architecture, spectral composition of sleep EEG, the nocturnal secretion of Cortisol, ACTH, GH, prolactin, melatonin, ghrelin, and leptin, and the DEX-CRH test in depressed patients during treat ment with mirtazapine.
        Neuropsychopharmacology. 2006; 31: 832-844
        • Aslan S.
        • Isik E.
        • Cosar B.
        The effects of mirtazapine on sleep: a placebo controlled, double-blind study in young healthy volunteers.
        Sleep. 2002; 25: 677-679
        • Krystal A.D.
        • Lankford A.
        • Durrence H.H.
        • et al.
        Efficacy and safety of doxepin 3 and 6 mg in a 35-day sleep laboratory trial in adults with chronic primary insomnia.
        Sleep. 2011; 34: 1433-1442
        • Goerke M.
        • Cohrs S.
        • Rodenbeck A.
        • et al.
        Differential effect of an anticholinergic antidepressant on sleep- dependent memory consolidation.
        Sleep. 2014; 37: 977-985
        • Kolla B.P.
        • Mansukhani M.P.
        • Bostwick J.M.
        The influ- ence of antidepressants on restless legs syndrome and periodic limb movements: a systematic review.
        Sleep Med Rev. 2018; 38: 131-140
        • Walsh J.K.
        Drugs used to treat insomnia in 2002: regulatory-based rather than evidence-based medi cine.
        Sleep. 2004; 27: 1441-1442
        • Cohrs S.
        • Rodenbeck A.
        • Guan Z.
        • et al.
        Sleep-pro- moting properties of quetiapine in healthy sub jects.
        Psychopharmacology (Berl). 2004; 174: 421-429
        • Tassniyom K.
        • Paholpak S.
        • Tassniyom S.
        • et al.
        Que tiapine for primary insomnia: a double blind, ran domized controlled trial.
        J Med Assoc Thai. 2010; 93: 729-734
        • Coe H.V.
        • Hong I.S.
        Safety of low doses of quetiapine when used for insomnia.
        Ann Pharmacother. 2012; 46: 718-722
        • Thompson W.
        • Quay T.A.W.
        • Rojas-Fernandez C.
        • et al.
        Atypical antipsychotics for insomnia: a systematic review.
        Sleep Med. 2016; 22: 13-17
        • Monti J.M.
        • Torterolo P.
        • Pandi Perumal S.R.
        The ef- fects of second generation antipsychotic drugs on sleep variables in healthy subjects and pa tients with schizophrenia.
        Sleep Med Rev. 2017; 33: 51-57
        • Vgontzas A.N.
        • Fernandez-Mendoza J.
        • Liao D.
        • et al.
        Insomnia with objective short sleep duration: the most biologically severe phenotype of the disorder.
        Sleep Med Rev. 2013; 17: 241-254
        • Stahl S.M.
        Temazepam.
        in: Stahl S.M. Stahl's essential pharmacology: the prescriber's guide. 6th edition. Cambridge University Press, Cambridge (UK)2017: 703-706
        • Yasui-Furukori N.
        • Takahata T.
        • Kondo T.
        • et al.
        Time ef fects of food intake on the pharmacokinetics and pharmacodynamics of quazepam.
        Br J Clin Pharmacol. 2003; 55: 382-388
      3. (Available at) (Accessed February 19, 2018)